sICASBLM is a prospective controlled trial, to asses the impact of improving blood lipid management on clinical outcome of moderate to severe symptomatic intracranial atherosclerotic stenosis patients (LDL-C\>1.8mmol/L) without endovascular therapy.
sICASBLM aims to determine the effectiveness of conventional lipid management combined with PCSK9 inhibitors compared to conventional lipid management (atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg) in reducing the incidence of recurrent stroke in patients with moderate to severe symptomatic intracranial atherosclerotic stenosis (LDL-C\>1.8mmol/L) without endovascular therapy.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
180
The aim is to improve blood lipid management by using atorvastatin 20-40mg or rosuvastatin 10-20mg or simvastatin 20-40mg and PCSK9 inhibitors for 6-12 months
Nanjing First Hospital, Nanjing Medical University
Nanjing, Jiangsu, China
RECRUITINGNanjing First Hospital
Nanjing, Jiangsu, China
RECRUITINGRecurrent stroke
the recurrent rate of clinical stroke
Time frame: 6 months-12 months
Intracranial arterial
Degree of change in intracranial arterial stenosis
Time frame: 6 months or 12 months
Plaque changes
Plaque volume and load changes
Time frame: 6 months or 12 months
Vascular remodeling index
Vascular remodeling index changes
Time frame: 6 months or 12 months
Adverse events
The incidence of muscle related events, allergic reactions, injection site reactions, bleeding events and other adverse events was assessed
Time frame: 6 months or 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.